AstraZeneca Shares Edge Lower Amid Cancer-Drug Collaboration Expansion
AstraZeneca (AZN) shares moved slightly lower to $157.10 on October 2 as the company expanded its cancer-drug collaboration with Summit Therapeutics. The updated agreement involves pairing Datroway with ivonescimab in Phase 3 trials. Shares were trading 13.86% below a prior valuation snapshot.